[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 130 pages | ID: N4EAE3DEF2B3EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2022, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 5, 3, 15, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase 0, Preclinical and Discovery stages comprises 2, 1, 2 and 2 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Neisseria meningitidis Infections - Overview
Neisseria meningitidis Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neisseria meningitidis Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
Neisseria meningitidis Infections - Drug Profiles
Neisseria meningitidis Infections - Dormant Projects
Neisseria meningitidis Infections - Discontinued Products
Neisseria meningitidis Infections - Product Development Milestones
Featured News & Press Releases
Jan 08, 2022: CanSinoBIO announces approval for its MCV4 product Menhycia in China
Sep 27, 2021: New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline including MenQuadfi and commitment to advancing public health protection
Jul 12, 2021: Sanofi’s meningococcal disease jab meets all endpoints in Phase III trial
Jan 15, 2021: Microsuper-biological tetravalent meningococcal conjugate vaccine formally submitted for IND application
Nov 23, 2020: European Commission approves MenQuadfi, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
Sep 17, 2020: Sanofi receives CHMP positive opinion for MenQuadfi intended for prophylaxis against invasive meningococcal disease
Jun 22, 2020: Pfizer announces start of Phase 3 Clinical Trial of MenABCWY
May 29, 2020: The European Medicines Agency has finalised its assessment of an application to extend the use of Trumenba for the prevention of invasive meningococcal disease
Aug 29, 2019: $440 million funding boost for vital health and medical research for all stages of life
Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis
Jun 27, 2018: European approval for lower dose of GSk's Meningitis vaccine
Jun 18, 2018: New way to determine protection of Men B vaccine against different strains
Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada
Feb 07, 2018: GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Neisseria meningitidis Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neisseria meningitidis Infections - Pipeline by AIM Vaccine Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Alopexx Inc, 2022
Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Biological E Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, 2022
Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, 2022
Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Eubiologics Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by GSK plc, 2022
Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2022
Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Intravacc BV, 2022
Neisseria meningitidis Infections - Pipeline by Inventprise LLC, 2022
Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, 2022
Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Omvax Inc, 2022
Neisseria meningitidis Infections - Pipeline by Pfizer Inc, 2022
Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, 2022
Neisseria meningitidis Infections - Pipeline by Sanofi, 2022
Neisseria meningitidis Infections - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, 2022
Neisseria meningitidis Infections - Dormant Projects, 2022
Neisseria meningitidis Infections - Dormant Projects, 2022 (Contd..2)
Neisseria meningitidis Infections - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Neisseria meningitidis Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications